Home / ADXN : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does ADXN make money? Does ADXN have pricing power? What's the Earnings Whisper? Will ADXN profit more as the business scales? What is ADXN's management track record? Is ADXN's current price justified?

Addex Therapeutics Ltd

$3.49 -$4.60 (-56.86%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$3.39

Day Range

$3.36$3.55

Year Range

$3.3$11.97

Market Cap

4.3M

AVG Volume

95.4K

Trailing/Forward PE

-0.43/-

PEG ratio

0.02

Dividend Yield

Next Earnings Date

2026-11-09

Primary Exchange

NASDAQ

Revenue (CHF)

ADXN Revenue (CHF) by quarter
Period	Revenue (CHF)
26 Q1	7.69K
25 Q4	248
25 Q3	29.72K
25 Q2	36.38K
25 Q1	0
24 Q4	1.51K
24 Q3	53.84K
24 Q2	115.28K
24 Q1	233.48K
23 Q4	153.45K

Net Income (CHF)

ADXN Net Income (CHF) by quarter
Period	Net Income (CHF)
26 Q1	-1.71M
25 Q4	-1.84M
25 Q3	-1.58M
25 Q2	-1.84M
25 Q1	-1.47M
24 Q4	-1.21M
24 Q3	-1.53M
24 Q2	12.88M
24 Q1	-3.09M
23 Q4	-2.86M

Operating Income (CHF)

ADXN Operating Income (CHF) by quarter
Period	Operating Income (CHF)
26 Q1	-479.83K
25 Q4	-779.26K
25 Q3	-696.17K
25 Q2	-732.9K
25 Q1	-606.26K
24 Q4	-445.63K
24 Q3	-622.2K
24 Q2	-899.32K
24 Q1	-788.09K
23 Q4	-2.68M

EBITDA (CHF)

ADXN EBITDA (CHF) by quarter
Period	EBITDA (CHF)
26 Q1	-1.7M
25 Q4	-1.83M
25 Q3	-1.57M
25 Q2	-1.96M
25 Q1	-1.47M
24 Q4	-1.16M
24 Q3	-1.47M
24 Q2	-1.34M
24 Q1	-664.21K
23 Q4	-2.77M

Cash Flows (CHF)

ADXN Cash Flows (CHF) by quarter
Period	Cash Flows (CHF)
26 Q1	-765.84K
25 Q4	-608.4K
25 Q3	-533.2K
25 Q2	-419.84K
25 Q1	-598.71K
24 Q4	-23.56K
24 Q3	-399.86K
24 Q2	-2.76M
24 Q1	-2.19M
23 Q4	-624.23K

EPS (CHF)

ADXN EPS (CHF) by quarter
Period	EPS (CHF)
26 Q1	-1.2
25 Q4	-1.54
25 Q3	-1.67
25 Q2	-2.4
25 Q1	-1.8
24 Q4	-1.48
24 Q3	-1.88
24 Q2	15.6
24 Q1	-3.8
23 Q4	-3.6

Expenses (CHF)

ADXN Expenses (CHF) by quarter
Period	Expenses (CHF)
26 Q1	398.71K
25 Q4	571.84K
25 Q3	545.17K
25 Q2	480.45K
25 Q1	480.66K
24 Q4	254.34K
24 Q3	416.37K
24 Q2	691.63K
24 Q1	750.85K
23 Q4	2.16M

Cash & Debt (CHF)

ADXN Cash & Debt (CHF) by quarter
Period	Cash & Debt (CHF)
26 Q1	937.5K
25 Q4	1.64M
25 Q3	2.19M
25 Q2	2.3M
25 Q1	2.83M
24 Q4	3.35M
24 Q3	3.35M
24 Q2	3.79M
24 Q1	1.63M
23 Q4	3.87M

Debt ratios

ADXN Debt ratios by quarter
Period	Debt ratios
26 Q1	0.12
25 Q4	0.24
25 Q3	0.35
25 Q2	0.37
25 Q1	0.51
24 Q4	0.71
24 Q3	0.53
24 Q2	0.69
24 Q1	0.35
23 Q4	0.85

Margins

ADXN Margins by quarter
Period	Margins
26 Q1	-369.76%
25 Q4	100%
25 Q3	100%
25 Q2	-544.55%
24 Q4	100%
24 Q3	100%
24 Q2	100%
24 Q1	100%
23 Q4	100%
23 Q3	100%

Return on Capital

ADXN Return on Capital by quarter
Period	Return on Capital
26 Q1	-52.08%
25 Q4	-38.54%
25 Q3	-26.47%
25 Q2	-25.53%
25 Q1	-17.75%
24 Q4	-12.46%
24 Q3	-13.83%
24 Q2	101.8%
24 Q1	224.46%
23 Q4	-249.4%

Shares Outstanding

ADXN Shares Outstanding by quarter
Period	Shares Outstanding
26 Q1	1.43M
25 Q4	1.19M
25 Q3	938.98K
25 Q2	721.04K
25 Q1	819.54K
24 Q4	815.2K
24 Q3	812.79K
24 Q2	812.79K
24 Q1	812.79K
23 Q4	793.64K

Book Value Per Share (CHF)

ADXN Book Value Per Share (CHF) by quarter
Period	Book Value Per Share (CHF)
26 Q1	2.3
25 Q4	4.02
25 Q3	6.35
25 Q2	10
25 Q1	10.12
24 Q4	11.87
24 Q3	13.61
24 Q2	15.57
24 Q1	-1.69
23 Q4	1.44

Total Assets (CHF)

ADXN Total Assets (CHF) by quarter
Period	Total Assets (CHF)
26 Q1	4.76M
25 Q4	6.37M
25 Q3	7.33M
25 Q2	8.51M
25 Q1	9.48M
24 Q4	10.68M
24 Q3	12.17M
24 Q2	13.7M
24 Q1	3.33M
23 Q4	4.64M

Employee Count

ADXN Employee Count by quarter
Period	Employee Count
2025	3
2024	2
2023	23
2022	24
2021	28
2020	27
2019	18

PE Ratio

ADXN PE Ratio by quarter
Period	PE Ratio
Sep 25	0.67
Sep 25	0.68
Sep 25	0.8
Sep 25	0.61
Aug 25	0.6
Aug 25	0.66
Aug 25	0.6
Aug 25	0.62
Aug 25	0.62
Jul 25	0.64
Jul 25	0.57
Jul 25	0.66
Jul 25	0.7
Jun 25	0.68
Jun 25	0.65
Jun 25	0.78
Jun 25	0.97
May 25	0.76
May 25	0.8
May 25	0.82
May 25	1.01
May 25	1
Apr 25	1.01
Apr 25	0.92
Apr 25	0.89
Apr 25	0.96
Mar 25	1.07
Mar 25	1.01
Mar 25	1
Mar 25	1.02
Feb 25	1.15
Feb 25	1.01
Feb 25	0.99
Feb 25	1.06
Jan 25	1.05
Jan 25	1.15
Jan 25	1.1
Jan 25	1.04
Jan 25	1.14
Dec 24	1.02
Dec 24	1.06
Dec 24	1.07
Dec 24	1.08
Nov 24	1.15
Nov 24	1.01
Nov 24	1.35
Nov 24	1.74
Nov 24	1.75
Oct 24	1.8
Oct 24	1.7
Oct 24	1.65
Oct 24	1.52
Sep 24	1.43
Sep 24	1.57
Sep 24	1.54
Sep 24	1.77
Aug 24	1.74

Free Cash Flow Yield

ADXN Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-57.25%
Sep 26	-55.17%
Aug 26	-52.49%
Aug 26	-41.21%
Aug 26	-33.73%
Aug 26	-34.82%
Jul 26	-38.87%
Jul 26	-33.86%
Jul 26	-35.47%
Jul 26	-31.85%
Jul 26	-35.06%
Jun 26	-33.21%
Jun 26	-36.55%
Jun 26	-35.46%
Jun 26	-39.08%
May 26	-35.1%
May 26	-33.99%
May 26	-34.01%
May 26	-31.62%
May 26	-30.68%
Apr 26	-30.57%
Apr 26	-31.95%
Apr 26	-32.25%
Apr 26	-36.72%
Mar 26	-31.37%
Mar 26	-37.65%
Mar 26	-30.84%
Mar 26	-30.19%
Feb 26	-30%
Feb 26	-30.03%
Feb 26	-29%
Feb 26	-27.39%
Jan 26	-28.35%
Jan 26	-26.89%
Jan 26	-25.11%
Jan 26	-26.86%
Jan 26	-26.19%
Dec 25	-26.61%
Dec 25	-26.94%
Dec 25	-26.03%
Dec 25	-26.85%
Nov 25	-32.51%
Nov 25	-31.49%
Nov 25	-29.78%
Nov 25	-29.25%
Oct 25	-27.3%
Oct 25	-26.2%
Oct 25	-23.03%
Oct 25	-26.53%
Oct 25	-27.36%
Sep 25	-64.69%
Sep 25	-64.52%
Sep 25	-54.16%
Sep 25	-71.45%
Aug 25	-72.93%
Aug 25	-65.96%
Aug 25	-72.05%
Aug 25	-70.06%
Aug 25	-70.87%
Jul 25	-67.74%
Jul 25	-76.34%
Jul 25	-65.61%
Jul 25	-61.91%
Jun 25	-64.2%
Jun 25	-66.7%
Jun 25	-97.06%
Jun 25	-78.42%
May 25	-100%
May 25	-95.63%
May 25	-92.66%
May 25	-109.22%
May 25	-110.29%
Apr 25	-108.92%
Apr 25	-119.67%
Apr 25	-123.86%
Apr 25	-115.09%
Mar 25	-103.78%
Mar 25	-109.64%
Mar 25	-110.25%
Mar 25	-108.54%
Feb 25	-95.86%
Feb 25	-109%
Feb 25	-111.12%
Feb 25	-104.49%
Jan 25	-104.79%
Jan 25	-95.94%
Jan 25	-100.9%
Jan 25	-106.78%
Jan 25	-96.76%
Dec 24	-108.46%
Dec 24	-104.24%
Dec 24	-103.03%
Dec 24	-102.72%
Nov 24	-95.86%
Nov 24	-109.26%
Nov 24	-134.59%
Nov 24	-104.31%
Nov 24	-103.54%
Oct 24	-100.96%
Oct 24	-106.75%

Price to Sales

ADXN Price to Sales by quarter
Period	Price to Sales
Sep 26	54.9
Sep 26	56.98
Aug 26	59.89
Aug 26	76.27
Aug 26	93.19
Aug 26	90.27
Jul 26	80.86
Jul 26	92.83
Jul 26	88.62
Jul 26	98.69
Jul 26	89.66
Jun 26	94.65
Jun 26	89.09
Jun 26	91.83
Jun 26	83.32
May 26	92.76
May 26	95.79
May 26	95.73
May 26	73.68
May 26	75.95
Apr 26	76.23
Apr 26	72.93
Apr 26	72.26
Apr 26	63.46
Mar 26	74.27
Mar 26	61.89
Mar 26	75.57
Mar 26	77.18
Feb 26	77.67
Feb 26	77.6
Feb 26	80.34
Feb 26	85.07
Jan 26	82.19
Jan 26	86.67
Jan 26	92.8
Jan 26	86.74
Jan 26	88.97
Dec 25	87.55
Dec 25	86.48
Dec 25	89.5
Dec 25	86.78
Nov 25	48.36
Nov 25	49.92
Nov 25	52.8
Nov 25	53.75
Oct 25	57.58
Oct 25	60.01
Oct 25	68.27
Oct 25	59.27
Oct 25	57.47
Sep 25	34.24
Sep 25	34.33
Sep 25	40.9
Sep 25	31
Aug 25	30.37
Aug 25	33.58
Aug 25	30.74
Aug 25	31.61
Aug 25	31.25
Jul 25	32.7
Jul 25	29.02
Jul 25	33.76
Jul 25	35.78
Jun 25	34.5
Jun 25	33.21
Jun 25	13.7
Jun 25	16.96
May 25	13.3
May 25	13.9
May 25	14.35
May 25	9.84
May 25	9.74
Apr 25	9.86
Apr 25	8.98
Apr 25	8.67
Apr 25	9.34
Mar 25	10.35
Mar 25	9.8
Mar 25	9.74
Mar 25	9.9
Feb 25	11.21
Feb 25	9.86
Feb 25	9.67
Feb 25	10.28
Jan 25	10.25
Jan 25	11.2
Jan 25	10.65
Jan 25	10.06
Jan 25	11.1
Dec 24	9.91
Dec 24	10.31
Dec 24	10.43
Dec 24	10.46
Nov 24	11.21
Nov 24	9.83
Nov 24	7.01
Nov 24	9.04
Nov 24	9.11
Oct 24	9.34
Oct 24	8.83

Price to Book

ADXN Price to Book by quarter
Period	Price to Book
Sep 26	1.24
Sep 26	1.28
Aug 26	1.35
Aug 26	1.72
Aug 26	2.1
Aug 26	2.03
Jul 26	1.82
Jul 26	2.09
Jul 26	2
Jul 26	2.22
Jul 26	2.02
Jun 26	2.13
Jun 26	1.24
Jun 26	1.28
Jun 26	1.16
May 26	1.29
May 26	1.33
May 26	1.33
May 26	0.84
May 26	0.86
Apr 26	0.86
Apr 26	0.83
Apr 26	0.82
Apr 26	0.72
Mar 26	0.84
Mar 26	0.7
Mar 26	0.86
Mar 26	0.88
Feb 26	0.88
Feb 26	0.88
Feb 26	0.91
Feb 26	0.97
Jan 26	0.93
Jan 26	0.98
Jan 26	1.05
Jan 26	0.98
Jan 26	1.01
Dec 25	0.99
Dec 25	0.98
Dec 25	1.02
Dec 25	0.98
Nov 25	0.61
Nov 25	0.63
Nov 25	0.67
Nov 25	0.68
Oct 25	0.73
Oct 25	0.76
Oct 25	0.87
Oct 25	0.75
Oct 25	0.73
Sep 25	0.7
Sep 25	0.71
Sep 25	0.84
Sep 25	0.64
Aug 25	0.62
Aug 25	0.69
Aug 25	0.63
Aug 25	0.65
Aug 25	0.64
Jul 25	0.67
Jul 25	0.6
Jul 25	0.69
Jul 25	0.74
Jun 25	0.71
Jun 25	0.68
Jun 25	0.57
Jun 25	0.71
May 25	0.56
May 25	0.58
May 25	0.6
May 25	0.49
May 25	0.49
Apr 25	0.5
Apr 25	0.45
Apr 25	0.44
Apr 25	0.47
Mar 25	0.52
Mar 25	0.49
Mar 25	0.49
Mar 25	0.5
Feb 25	0.56
Feb 25	0.5
Feb 25	0.49
Feb 25	0.52
Jan 25	0.52
Jan 25	0.56
Jan 25	0.54
Jan 25	0.51
Jan 25	0.56
Dec 24	0.5
Dec 24	0.52
Dec 24	0.52
Dec 24	0.53
Nov 24	0.56
Nov 24	0.49
Nov 24	0.46
Nov 24	0.59
Nov 24	0.6
Oct 24	0.61
Oct 24	0.58

No video analysis for this stock yet. Request one from our team.

News: ADXN

globenewswire.com · 26 Aug 2026

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it's At the Market (ATM) offering agreement with H.C.

seekingalpha.com · 25 Jun 2026

Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript

globenewswire.com · 25 Jun 2026

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2026 financial results and provided a corporate update.

globenewswire.com · 22 Jun 2026

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its First Quarter 2026 Financial Results on June 25, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on June 25, 2026.